Roghani Hassan Salman, Massarrat Sedegh, Shirekhoda Mohammad, Butorab Zia
Department of Internal Medicine, Yazd University of Medical Sciences, Yazd, Iran.
J Gastroenterol Hepatol. 2003 Jul;18(7):778-82. doi: 10.1046/j.1440-1746.2003.03058.x.
Resistance to metronidazole is one of the most common reasons for Helicobacter pylori treatment failure with classic triple therapy. In contrast, the clarithromycin-based regimen is not cost-effective for developing countries. Furazolidone is a very good substitute for metronidazole and clarithromycin, but its many side-effects limit widespread use. The aim of the present study was to assess the efficacy of two different doses of furazolidone in combination with amoxycillin and omeprazole.
A total of 123 patients with duodenal ulcer were randomized and received the following medications for two weeks. Group A: furazolidone 2 x 200 mg + amoxycillin 2 x 1 g + omeprazole 2 x 20 mg/day. Group B: furazolidone 2 x 50 mg + amoxycillin 2 x 1 g + omeprazole 2 x 20 mg/day. Control endoscopy was performed after 6 weeks and two biopsy specimens from the antrum and two from the corpus were taken for a urease test and histology. Eradication was concluded if all tests were negative for H. pylori.
In total, 110 patients completed the study. Four patients in group A did not tolerate the regimen on day 8 of therapy and were excluded from the study. Serious complications such as fever, and fatigue and dizziness, which occurred in the beginning of the second week of treatment (days 8-10), were more common in group A than in group B (19%, 15.9% and 14.3%, respectively, in group A vs 0% in group B). The eradication rate by per protocol analysis was significantly higher in group A than in group B (88.9%vs 67.9%, respectively, P = 0.008). However, this difference was low and not statistically significant by intention-to-treat analysis (76.2% in group A and 62.3% in group B, P = 0.09).
The regimen with a non-reduced dose of furazolidone in combination with amoxycillin and omeprazole was effective when the patients tolerated the drugs and completed the study.
甲硝唑耐药是幽门螺杆菌经典三联疗法治疗失败的最常见原因之一。相比之下,基于克拉霉素的治疗方案对发展中国家而言不具有成本效益。呋喃唑酮是甲硝唑和克拉霉素的良好替代品,但其诸多副作用限制了广泛应用。本研究的目的是评估两种不同剂量的呋喃唑酮联合阿莫西林和奥美拉唑的疗效。
总共123例十二指肠溃疡患者被随机分组,并接受以下药物治疗两周。A组:呋喃唑酮2×200mg + 阿莫西林2×1g + 奥美拉唑2×20mg/天。B组:呋喃唑酮2×50mg + 阿莫西林2×1g + 奥美拉唑2×20mg/天。6周后进行对照内镜检查,并从胃窦取两份活检标本,从胃体取两份活检标本进行尿素酶试验和组织学检查。如果所有检测幽门螺杆菌的结果均为阴性,则判定根除成功。
共有110例患者完成了研究。A组有4例患者在治疗第8天不耐受该治疗方案而被排除在研究之外。治疗第二周开始(第8 - 10天)出现的严重并发症如发热、乏力和头晕,A组比B组更常见(A组分别为19%、15.9%和14.3%,B组为0%)。按符合方案分析,A组的根除率显著高于B组(分别为88.9%对67.9%,P = 0.008)。然而,在意向性分析中,这种差异较小且无统计学意义(A组为76.2%,B组为62.3%,P = 0.09)。
当患者耐受药物并完成研究时,未减量的呋喃唑酮联合阿莫西林和奥美拉唑的治疗方案是有效的。